Genvax Technologies Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Seed
- Investors
-
11
Genvax Technologies General Information
Description
Developer of animal vaccines designed to accelerate treatments for the animal health industry. The company's saRNA platform allows for the rapid development of herd or flock-specific vaccines matched to the variant strain circulating in an animal-production operation by inserting a specific transgene or gene of interest matched to the variant strain into the platform, providing clients from the animal health industry with novel vaccines for the prevention and treatment of animal diseases.
Contact Information
Website
www.genvax.comCorporate Office
- 2503 South Loop Drive
- Suite 5446
- Ames, IA 50010
- United States
Corporate Office
- 2503 South Loop Drive
- Suite 5446
- Ames, IA 50010
- United States
Genvax Technologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Seed Round | 03-Feb-2025 | Completed | Clinical Trials - General | |||
| 2. Seed Round | 09-Aug-2022 | Completed | Clinical Trials - General | |||
| 1. Grant | 18-Apr-2022 | $145K | Completed | Clinical Trials - General |
Genvax Technologies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-1 | ||||||||
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Genvax Technologies Patents
Genvax Technologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260124157-A1 | Methods of self-amplifying rna-lipid nanoparticle manufacture and compositions derived therefrom | Pending | 09-Aug-2024 | ||
| WO-2026033498-A1 | Methods of self-amplifying rna-lipid nanoparticle manufacture and compositions derived therefrom | Pending | 09-Aug-2024 |
Genvax Technologies Signals
Genvax Technologies Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 1945 Capital | Family Office | Minority | ||
| Grit Road Partners | Venture Capital | Minority | ||
| InnoVenture Iowa | Venture Capital | Minority | ||
| Next Level Ventures | Venture Capital | Minority | ||
| Ag Startup Engine | Venture Capital | Minority |
Genvax Technologies FAQs
-
When was Genvax Technologies founded?
Genvax Technologies was founded in 2021.
-
Where is Genvax Technologies headquartered?
Genvax Technologies is headquartered in Ames, IA.
-
What is the size of Genvax Technologies?
Genvax Technologies has 9 total employees.
-
What industry is Genvax Technologies in?
Genvax Technologies’s primary industry is Other Agriculture.
-
Is Genvax Technologies a private or public company?
Genvax Technologies is a Private company.
-
What is Genvax Technologies’s current revenue?
The current revenue for Genvax Technologies is .
-
How much funding has Genvax Technologies raised over time?
Genvax Technologies has raised $8.4M.
-
Who are Genvax Technologies’s investors?
1945 Capital, Grit Road Partners, InnoVenture Iowa, Next Level Ventures, and Ag Startup Engine are 5 of 11 investors who have invested in Genvax Technologies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process